- Step therapy (“fail first”) requires you to try older, lower-cost medications before insurers will cover newer GLP-1s
- Older weight loss medications typically produce 5–7% body weight loss vs. 15–20% with newer GLP-1 agonists
- You may be able to skip step therapy with a medical exception or prior documentation of medication failure
- PEAK documents everything from day one with step therapy and PA requirements in mind
What is step therapy?
Step therapy — sometimes called “fail first” — is an insurance requirement that you try one or more lower-cost medications before your plan will cover a newer or more expensive drug. For weight loss medications, this usually means trying older options before you can access GLP-1 receptor agonists like Wegovy (semaglutide) or Zepbound (tirzepatide).
The concept is straightforward: your insurer wants to see whether a less expensive medication works for you before they approve a costlier alternative. In practice, the process is more complicated than it sounds.
Step 1: Contrave (naltrexone/bupropion) — an oral combination medication that affects appetite and reward pathways. Average weight loss: approximately 5–6% of body weight.
Step 2: Qsymia (phentermine/topiramate) — a combination of a stimulant and an anticonvulsant. Average weight loss: 7–10% of body weight.
Step 3: Saxenda (liraglutide 3.0mg) — a first-generation GLP-1 agonist. Average weight loss: 5–8% of body weight.
Then: Wegovy (semaglutide 2.4mg) or Zepbound (tirzepatide) — next-generation GLP-1/GIP agonists. Average weight loss: 15–20%+ of body weight.
Not every insurer requires all of these steps. Some plans require only one prior medication trial; others require two or more. The specific requirements depend entirely on your plan.
Why insurers require it
Step therapy exists primarily for cost management. Newer GLP-1 medications like Wegovy and Zepbound cost significantly more than older options. From an insurer’s perspective, if an older, less expensive medication achieves adequate results, there is no reason to approve the more expensive alternative.
There is some clinical basis for this approach. A percentage of patients will respond well to first-line medications and may not need the newer agents. But the clinical reality is more nuanced than the policy suggests.
Step therapy treats all patients as interchangeable. Your biology, your history, and your specific barriers to weight loss are not interchangeable.
Insurers also argue that step therapy prevents unnecessary prescribing and ensures that the most expensive medications are reserved for patients who truly need them. In theory, this is reasonable. In practice, it means many patients spend months on medications that are unlikely to produce the results they need.
The problem with step therapy
The core issue with step therapy for weight loss medications is the efficacy gap. Older medications simply do not produce the same results as newer GLP-1 agonists. The clinical data is clear:
- Contrave produces an average of approximately 5–6% total body weight loss. For a 250-pound patient, that is roughly 12–15 pounds.
- Wegovy produces an average of 15–17% total body weight loss. For the same 250-pound patient, that is roughly 37–42 pounds.
- Zepbound produces an average of 18–22% total body weight loss in clinical trials. For the same patient, that is 45–55 pounds.
The difference is not marginal — it is clinically significant. For patients with obesity-related comorbidities like type 2 diabetes, hypertension, or cardiovascular disease, the additional weight loss from newer agents can mean the difference between managing a condition and meaningfully improving it.
Step therapy typically requires 3 to 6 months on each medication before your insurer considers the “step” completed. If your plan requires two steps, you may spend 6 to 12 months on medications that are less likely to help you reach your goals — before you can even try the medication your clinician recommended in the first place.
There are also tolerability issues. Some step therapy medications have side effects that make them difficult for certain patients to take. Phentermine (a component of Qsymia) is a stimulant and is contraindicated in patients with cardiovascular conditions. Bupropion (a component of Contrave) carries seizure risk. Requiring patients to trial medications that may not be appropriate for their health profile adds unnecessary clinical risk.
How to satisfy the requirements
If your insurance plan requires step therapy, the most important thing you can do is document everything. Your clinician’s documentation is what determines whether your insurer considers the step completed.
Here is what effective documentation looks like:
- Baseline measurements. Before starting a step therapy medication, your clinician should document your weight, BMI, relevant lab values, and all current comorbidities.
- Treatment timeline. Record the start date, dosage, and any dose adjustments. Insurers need to see that you took the medication for the full required period.
- Response tracking. Document weight changes, side effects, and any changes in comorbidities at regular intervals (typically monthly).
- Reason for discontinuation. When the step therapy medication is stopped, the reason must be clearly documented — whether it is insufficient efficacy, intolerable side effects, or a contraindication.
- Formal conclusion. Your clinician writes a clinical summary stating that the medication was tried, the results were inadequate, and a GLP-1 agonist is now medically necessary.
We have seen patients complete step therapy only to have their GLP-1 denied because the documentation was not detailed enough. The step therapy medication “failed,” but the clinical record did not clearly say so. At PEAK, we document with the insurer’s requirements in mind from the first visit.
Exceptions to step therapy
You may not have to complete step therapy at all. Most insurers allow exceptions in specific circumstances:
- Medical contraindication. If the required step therapy medication is contraindicated for you — for example, if you have a seizure disorder and Contrave is required — your clinician can request an exception.
- Prior medication trial. If you have already tried and failed the required medication, even under a different insurance plan or a previous employer, your clinician can submit documentation of that prior trial. You should not have to repeat a medication you have already tried.
- Clinical urgency. In some cases, your clinician can argue that the severity of your condition warrants skipping step therapy. This is more common when obesity is causing immediate health risks (e.g., uncontrolled diabetes, cardiovascular events).
- State legislation. Some states have passed step therapy reform laws that limit how long insurers can require patients to stay on step therapy medications or that mandate exception processes. Check whether your state has such protections.
Requesting a step therapy exception requires a formal submission from your prescribing clinician. It is not something you can do on your own through your insurer’s member portal.
What we do at PEAK
At PEAK, we approach step therapy strategically. Our goal is to get you on the most effective medication as quickly as your insurance allows — and to avoid unnecessary delays.
Here is how we handle it:
- Pre-visit benefits check. Before your first appointment, we verify whether your plan requires step therapy and what specific medications are required. This way, you know what to expect before you start.
- Exception requests. If you have a medical contraindication or a prior medication trial, we submit the exception request immediately — often before prescribing anything.
- Efficient step therapy. If you do need to complete step therapy, we prescribe the required medication, document everything meticulously, and prepare the GLP-1 prior authorization so it can be submitted the day you complete the required period.
- Parallel pathways. In some cases, we can explore alternative coverage pathways (such as a cardiovascular or sleep apnea indication) while step therapy is in progress.
Common questions
How long does step therapy take?
Most insurers require 3 to 6 months on each step therapy medication. If your plan requires two steps, the total process can take 6 to 12 months. The exact timeline depends on your specific plan.
What if I already tried the medication years ago?
If you can document a prior trial — through medical records, pharmacy records, or a letter from a previous clinician — most insurers will accept it. You should not have to repeat a medication you have already failed. Your clinician needs to submit this documentation as part of the exception request.
Can my doctor just prescribe the GLP-1 directly?
Your clinician can prescribe any medication they believe is appropriate. The issue is whether your insurance will pay for it. If your plan has a step therapy requirement and you have not completed it (or received an exception), the pharmacy claim will be rejected. You would need to pay the full cash price, which for GLP-1 medications is often high without coverage.
What if the step therapy medication causes side effects?
Intolerable side effects are a valid reason to discontinue a step therapy medication. Your clinician should document the specific side effects, their severity, and why the medication cannot be continued. This documentation supports either moving to the next step or requesting an exception to skip remaining steps.
Important safety information: Wegovy and Zepbound carry a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma) based on animal studies. They are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Contrave carries a boxed warning for suicidal thoughts and behavior. Discuss your full medical history with your clinician before starting any weight loss medication.
PEAK accepts commercial insurance and TRICARE. We do not accept Medicare or Medicaid, including Medicare Advantage and Medicaid managed care plans.
